Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 19;11(2):273. doi: 10.3390/antibiotics11020273

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Peptide L8S1 is active in combination with vancomycin or rifampicin against A. baumannii in vivo. Zebrafish larvae survival rates were tracked over time following A. baumannii infection and treatment with stapled peptides, vancomycin or combinations of stapled peptide and vancomycin via caudal vein injection (A). MIC values of L8S1, rifampicin or erythromycin, MIC values of L8S1 combined with either rifampicin or erythromycin and MIC values of rifampicin or erythromycin combined with L8S1 were determined via checkerboard assay. The FIC values were defined as either the ratio of L8S1 in combination with rifampicin or erythromycin over the MIC value of L8S1 alone (FIC_L8S1), or the ratio of the MIC value of rifampicin or erythromycin combined with L8S1 over the MIC value of rifampicin or erythromycin alone (FIC_antibiotic) (B). Survival rates of A. baumannii infected zebrafish larvae were additionally followed upon treatment with peptide L11S1, rifampicin or a combination of L11S1 and rifampicin (C). The data are presented as mean ± standard deviation from three independent experiments.